Prevotella corporis

(aka Bacteroides corporis)

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Prevotella corporis, (aka Bacteroides corporis), is a Gram-negative, non-spore-forming, strictly anaerobic, non-motile, coccus bacterium. It has been detected in at least 6 gut microbiome compilation studies or metastudies. The DNA G+C content is 43-46%. Prevotella corporis is a common gut coloniser. (Shah1990; Shah2010Bergeys; Johnson1983)



  • This organism has been recovered from clinical sources (cervical swab - CCUG) and human faeces. The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread. It is an opportunistic pathogen. A possible gut commensal.
    • QUIRKS
  • In 99% of Europeans (unseenbio.com).
    • GENERAL CHARACTERISTICS (Shah1990); (Shah2010Bergeys); (Johnson1983);
    Character Response
  • Substrates hydrolysed or digested:
  • gelatin; milk; starch;
  • 💧
  • Bile tolerance:
  • Doesn't tolerate 20% bile
  • H+
  • Acid from carbohydrates usually produced:
  • fructose; glucose; mannose; glycogen; starch; maltose;
  • Active enzymes:
  • Ala arylamidase; alkaline phosphatase; arginine dihydrolase; α-glucosidase; Glu-Glu arylamidase; Leu-Gly arylamidase;
  • ±
  • Strain-dependent active enzymes:
  • Leu arylamidase;
    • SPECIAL FEATURES (Shah1990); (Shah2010Bergeys); (Johnson1983);
    Character Response
  • ✓
  • Metabolites produced:
  • acetate; isobutyrate (minor); succinate; isovalerate (minor);
  • ✗
  • Metabolites not produced:
  • H₂S; H₂; indole;
  • ✗
  • Nitrate:
  • not reduced
  • ±
  • Pigments:
  • dark brown
    • RESPONSE TO ANTIBIOTICS (Citron2011); (Goldstein2000a);
    Class Active Resistant
  • Penicillins:
  • amoxicillin-clavulanic acid; ampicillin-sulbactam; doripenem; ertapenem; imipenem; meropenem; piperacillin-tazobactam; ticarcillin-clavulanic acid;
  • Cephalosporins:
  • cefalexin; cefamandole; cefoperazone; cefotetan; cefotiam; cefoxitin; ceftizoxime; moxalactam;
  • ceftazidime;
  • Macrolides:
  • azithromycin; erythromycin; quinupristin-dalfopristin;
  • Tetracyclines:
  • tetracycline;
  • Quinolines:
  • ciprofloxacin; garenoxacin; gatifloxacin; levofloxacin; moxifloxacin; trovafloxacin;
  • Heterocycles:
  • chloramphenicol; metronidazole;
  • Vancomycins:
  • vancomycin;
  • Miscellaneous antibiotics:
  • clindamycin; linezolid; ranbezolid;

  • Prevotella species at mucosal sites to localized and systemic disease, including periodontitis, bacterial vaginosis, rheumatoid arthritis, metabolic disorders and low_grade systemic inflammation. Intriguingly, Prevotella abundance is reduced within the lung microbiota of patients with asthma and chronic obstructive pulmonary disease. Increased Prevotella abundance is associated with augmented T helper type 17 (Th17) _mediated mucosal inflammation, which is in line with the marked capacity of Prevotella in driving Th17 immune responses in vitro. Studies indicate that Prevotella predominantly activate Toll_like receptor 2, leading to production of Th17_polarizing cytokines by antigen_presenting cells, including interleukin_23 (IL_23) and IL_1. Furthermore, Prevotella stimulate epithelial cells to produce IL_8, IL_6 and CCL20, which can promote mucosal Th17 immune responses and neutrophil recruitment. Prevotella_mediated mucosal inflammation leads to systemic dissemination of inflammatory mediators, bacteria and bacterial products, which in turn may affect systemic disease outcomes. [PMID: 28542929]

  • GutFeeling KnowledgeBase COMMENTS [Website]

    Prevotella species are anaerobic Gram_negative bacteria of the Bacteroidetes phylum, which also includes the clinically important genera Bacteroides and Porphyromonas. Prevotella strains are classically considered commensal bacteria due to their extensive presence in the healthy human body and their rare involvement in infections. Only a few strains have been reported to give rise to opportunistic endogenous infections, including chronic infections, abscesses and anaerobic pneumonia. [PMID: 28542929]

  • Walker, A. W., Sanderson, J. D., Churcher, C., Parkes, G. C., Hudspith, B. N., Rayment, N., Brostoff, J., Parkhill, J., Dougan, G., & Petrovska, L. (2011). High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiology, 11, 7.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Bacteroidetes Class:  Bacteroidia Order:  Bacteroidales Family:  Prevotellaceae Genus:  Prevotella Alt. name:  Bacteroides corporis Gram stain:  neg O2 Relation.:  strictly anaerobic Spore:  No spore Motility:  Sessile Morphology:  Coccus Pigment:  dark brown
    Health:  Unknown
    Source:  clinical sources (cervical swab - CCUG) and human faeces
    DNA G+C(%):  43-46
    Bile reaction(%):  20(neg)
    		Aesculin:  neg Urea:  neg Gelatin:  + Starch:  + Milk:  d(+) Meat:  vr
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  neg D-Arabinose:  neg Fructose:  d(+) Glucose:  + Mannose:  d(+) Rhamnose:  neg Ribose:  neg Xylose:  neg Cellubiose:  neg Lactose:  neg Maltose:  + Melezitose:  neg Melibiose:  neg Sucrose:  neg Trehalose:  neg Amygdalin:  neg Aesculin:  neg Glycogen:  + Inulin:  neg Starch:  + Xylan:  neg Erythritol:  neg Inositol:  neg Mannitol:  neg Sorbitol:  neg Salicin:  neg
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Lactate:  neg Pyruvate:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Catalase:  neg Urease:  neg G6PDH6PGDH:  neg Ac-β-glcamnd:  vr α-Fucosidase:  neg α-Galactosidase:  neg β-Galactosidase:  neg α-Glucosidase:  + β-Glucosidase:  neg β-Glucuronidase:  neg ArgDH:  + GluDC:  neg GlyAP:  neg AlanineAA:  + GluGluAA:  + GlyAA:  neg LeuAA:  d LeuGlyAA:  + PyrrolidAA:  neg AlkalineP:  +
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Acetate:  + Isobutyrate:  minor(+) Succinate:  + Isovalerate:  minor(+) H2S:  neg H2:  neg Indole:  neg Pigment:  dark brown
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    amoxicillin:  Var(MIC50): ≤0.125, MIC90: 32, RNG: (≤0.0125-64)
    Augmentin:  S(MIC50): 0.125, MIC90: 0.5, RNG: (≤0.025-2)
    amp-sulb:  S(MIC50): 1, MIC90: 4, RNG: (0.125-4)
    penicillin_G:  Var(MIC50): 0.5, MIC90: 8, RNG: (≤0.03-8)
    piper-taz:  S(MIC50): 0.125, MIC90: 0.125, RNG: (0.125-0.125)
    tica-clav:  S(MIC50): 0.06, MIC90: 0.5, RNG: (0.06–1)
    doripenem:  S(MIC50): 0.03, MIC90: 0.06, RNG: (0.03-0.06)
    ertapenem:  S(MIC50): 0.03, MIC90: 0.06, RNG: (≤0.016-0.125)
    imipenem:  S(MIC50): 0.03, MIC90: 0.06, RNG: (≤0.016-0.125)
    meropenem:  S(MIC50): 0.03, MIC90: 0.06, RNG: (≤0.016-0.06)
    cefalexin:  S(MIC50): 1, MIC90: 4, RNG: (0.25-32)
    cefamandole:  S(MIC50): 0.5, MIC90: -, RNG: (0.125-8)
    cefoperazone:  S(MIC50): 1, MIC90: -, RNG: (0.5-2)
    cefotetan:  S(MIC50): 0.5, MIC90: -, RNG: (0.25-8)
    cefotiam:  S(MIC50): 0.5, MIC90: -, RNG: (0.06-128)
    cefoxitin:  S(MIC50): 1, MIC90: 16, RNG: (0.06–16)
    ceftazidime:  R(MIC50): 32, MIC90: >128, RNG: (1->128)
    ceftizoxime:  S(MIC50): 0.5, MIC90: -, RNG: (0.06-2)
    moxalactam:  S(MIC50): 0.5, MIC90: -, RNG: (0.5-4)
    azithromycin:  S(MIC50): 0.06, MIC90: 1, RNG: (≤0.03-8)
    erythromycin:  S(MIC50): 0.125, MIC90: 1, RNG: (≤0.03-16)
    quin-dalf:  S(MIC50): 1, MIC90: 2, RNG: (≤0.0125-4)
    linezolid:  S(MIC50): 1, MIC90: 2, RNG: (0.25-2)
    ciprofloxacin:  S(MIC50): 1, MIC90: 2, RNG: (≤0.5-4)
    garenoxacin:  S(MIC50): 0.125, MIC90: 0.25, RNG: (0.125-0.5)
    gatifloxacin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.06-2)
    levofloxacin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.125-4)
    moxifloxacin:  S(MIC50): 0.5, MIC90: 0.5, RNG: (0.03-2)
    trovafloxacin:  S(MIC50): 1, MIC90: 1, RNG: (0.5-1)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    tetracycline:  R(MIC50): 4, MIC90: 32, RNG: (0.06-32)
    teicoplanin:  Var(MIC50): 2, MIC90: 16, RNG: (≤0.06->16)
    vancomycin:  R(MIC50): >16, MIC90: >16, RNG: (1->16)
    chloramphenicol:  S(MIC50): 2, MIC90: 4, RNG: (1–8)
    metronidazole:  S(MIC50): 1, MIC90: 2, RNG: (≤0.125-2)
    ranbezolid:  S(MIC50): 0.03, MIC90: 0.125, RNG: (≤0.008-0.25)
    clindamycin:  S(MIC50): ≤0.016, MIC90: 0.016, RNG: (≤0.016->32)

    References

    SPECIFIC REFERENCES FOR PREVOTELLA CORPORIS
  • Shah1990 - Notes: Prevotella, a New Genus To Include Bacteroides melaninogenicus and Related Species Formerly Classified in the Genus Bacteroides.
  • Shah2010Bergeys - Bergey's manual of systematic bacteriology. Vol. 4, The Bacteroidetes. Family Prevotellaceae, Genus I. Prevotella
  • Kishikawa2020 - Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population
  • Citron2011 - In vitro activity of ceftazidime-NXL104 against 396 strains of beta-lactamase-producing anaerobes.
  • Goldstein2000a - Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections.
  • Johnson1983 - Bacteroides intermedius comb. nov. and Descriptions of Bacteroides corporis sp. nov. and Bacteroides levii sp. nov.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR PREVOTELLA CORPORIS
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Urban2020 - Altered Fecal Microbiome Years after Traumatic Brain Injury
  • Walker2011 - High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease.
  • Yang2020 - Species-Level Analysis of Human Gut Microbiota With Metataxonomics.
  • Yang2020a - Establishing high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in patients with healthy families
  • ...............................
    • Added: April 08, 2021